Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
about
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.Cabozantinib for the treatment of kidney cancer.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.Targeted therapies for renal cell carcinoma.Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.My personal highlights of ESMO 2016.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review.A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.Multimodal treatment of advanced renal cancer in 2017.Treatment of renal cell carcinoma: Current status and future directions.Clinical development of mTor inhibitors for renal cancer.Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications.Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Kidney cancer in 2017: Challenging and refining treatment paradigms.[TKI 2.0 - changes in the medical treatment of renal cell carcinoma].Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.New treatment options for metastatic renal cell carcinoma.The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria.Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to dateAnlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentCabozantinib for the Management of Metastatic Clear Cell Renal Cell CarcinomaSafety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
P2860
Q37672483-FF687B08-860B-4568-A422-87B702E40643Q38668871-73877300-F1E1-41BE-A998-128A8DA7B9D5Q38673512-196B2518-7A30-4310-A2EA-8A19031DC81FQ38746778-9C42669E-84DD-4F5C-8780-DF72F690725EQ38754614-13ECB1E1-6AEF-45F2-A495-48B5043DD931Q39425380-26C46040-DB0F-41B1-92FC-11DC336C8D25Q42257155-835E1BA3-8D18-47DE-84B1-E2841565E7AFQ42315473-14712A32-29B2-4119-8A94-D07C6AFCCF2EQ42364404-195D0B24-1403-424C-B240-A1D960BD7BFDQ47103399-0B497076-DD5B-43A7-A2E6-11732779E786Q47143379-DBB80E87-B20E-466D-92C4-C592F049A51BQ47177700-97355EEB-EF00-40CB-BBAD-8A4B6B244946Q47550490-CBFFB2B6-55B8-4DAC-8167-D726DD9BAA37Q47726014-EACA3E87-B6D4-49E1-931E-2DEB24A01BA8Q47737687-26495A43-5827-466B-863D-F8E940AB9F04Q48171089-E121DDF7-543C-456E-B98B-97574FE460B1Q48273276-28A94636-BDBE-4640-BCF2-2E2C837FE1DCQ49573718-4615164A-7315-4A33-9192-0A48044DA6B7Q49953442-8818667E-4BD4-4D96-9DD3-0FCA38E8A745Q50042576-3DB53197-1D20-44EC-B19F-6BCD54743CE8Q50209991-31D71B7F-9445-42CF-BBCB-394B46417BBEQ50297707-73D2BAB9-6AA0-494A-8967-6B596841B385Q52644831-A1B09CC0-0684-4373-99D8-60DEF2901ACAQ52645823-CC7FF256-1367-429B-A7A3-23B15B200570Q52650529-A36ECD5F-9C21-4115-A6E4-6B79C55A8A55Q52661758-E1F3FEA4-B4F2-4C48-9F35-B81A2C9E9EDBQ52682465-87613020-5DE3-423E-ACEC-7F97A05D077CQ54976476-21268106-FDAE-4C49-84EF-67DC4CB75F01Q54980900-C0D6A683-D98D-4B21-85DD-6E568549E229Q54982000-18A3F7B2-174A-4CE2-8FBE-D849CD7A0FB6Q54987382-21FB0A12-797C-4737-8AE1-817839EAD741Q54990172-705035F9-741E-4563-AF29-E2C945B7C7C5Q55378351-15947F78-F445-45E2-8C8D-1E606F24E7D3Q57071032-906BD150-8C1C-4E08-AB0B-260FC27CAA6EQ57154768-4FA636E7-460B-489B-BA7F-E7516B8C0285Q57481747-513CE833-3496-4796-A58D-C3A8EA311DFCQ57803800-3E15DD89-CF3B-4BCF-A0BA-A35FD953DCE6
P2860
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@ast
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@en
type
label
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@ast
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@en
prefLabel
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@ast
Cabozantinib Versus Sunitinib ...... lliance A031203 CABOSUN Trial.
@en
P2093
P2860
P50
P356
P1476
Cabozantinib Versus Sunitinib ...... Alliance A031203 CABOSUN Trial
@en
P2093
Ben L Sanford
Daniel J George
Eric J Small
Joel Picus
M Dror Michaelson
Meghara K Walsh
Olwen Hahn
Shaker Dakhil
Thomas Olencki
Toni K Choueiri
P2860
P304
P356
10.1200/JCO.2016.70.7398
P407
P577
2016-11-14T00:00:00Z